The Omnipod® 5 Knowledge Hub
Tools to help you and your patients get started with Omnipod®
Help your patients get the most from their Omnipod® 5 Automated Insulin Delivery system with these downloadable resources, guides, videos and more
Omnipod® 5 Guides
- Omnipod® 5 User Guide: (View guide),
- Omnipod® 5 Technical User Guide: (View guide)
- Omnipod® 5 Caregiver Guide: (View guide)
- Omnipod® 5 & Glooko® Key information: (View guide)
Getting started on Omnipod® 5
Thank you for choosing to prescribe the Omnipod® 5 Automated Insulin Delivery system, integrated with the leading sensor brands**.
For more information to support your patients starting successfully on Omnipod 5 check here.
If you require a hard copy of the Omnipod® 5 User Guide or Omnipod® 5 Technical user guide give us a call at 0800 011 6132* or +44 20 3887 1709 if calling from abroad. We'll be happy to help you.
*Your call may be recorded for quality monitoring, and training purposes. Calls to 0800 numbers are free from local landlines but other networks or network carriers may charge for these calls.
Getting started on the Omnipod® 5 Automated Insulin Delivery System
Frequently Asked Questions
We have heard from many people in the community regarding their interest in the Omnipod® 5 system. Here are answers to some of the community’s most frequently asked questions.
Getting started on Omnipod® 5: Videos
These videos tutorials help you and your patients gain a better understanding of the information included in the Omnipod® System training. These can be shared with patients to help them prepare for their training.
Omnipod® 5: The Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ Technology automatically increases, decreases, or pauses basal insulin delivery, every five minutes, to personal needs which may help to correct highs and protect from lows1,2. Watch this video to learn more.
Initialisation: Learn how SmartAdjust™ works and tips for initialisation with your patients.
Optimisation: Once your patient has successfully started using the system, learn how to optimise it for best results.
Additional Resources
Omnipod® 5 Automated Insulin Delivery System
Meet the next generation Omnipod 5 Automated Insulin Delivery System. Read more.
SmartAdjust™ Technology
SmartAdjust™ Technology automatically increases, decreases, or pauses insulin delivery, every five minutes, to patients’ personal needs which may help to correct highs and protect against lows.1,2 Read more.
Safety and Glycaemic Outcomes
Safety and Glycaemic Outcomes with a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Read more.
Multicenter Trial of a Tubeless System
Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycaemic Targets in Paediatric and Adult Participants With Type 1 Diabetes. Read more.
Omnipod® 5 Webinars
Join our monthly Virtual Omnipod® Academy webinars to get a comprehensive overview of Omnipod® 5 and gain insight on best practices from key opinion leaders. Sign up
Hear experiences from some of the first Omnipod® 5 Podders®
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM. Mean HbA1c in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 7.16% vs 6.78%, P<0.0001; 7.67% vs 6.99%, P<0.0001, respectively.
2. Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05.